Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
| Revenue (TTM) | $24.78B |
| Gross Profit (TTM) | $14.62B |
| EBITDA | $7.93B |
| Operating Margin | 22.90% |
| Return on Equity | 7.08% |
| Return on Assets | 4.19% |
| Revenue/Share (TTM) | $34.87 |
| Book Value | $74.82 |
| Price-to-Book | 2.65 |
| Price-to-Sales (TTM) | 5.45 |
| EV/Revenue | 6.17 |
| EV/EBITDA | 21.60 |
| Quarterly Earnings Growth (YoY) | 9.80% |
| Quarterly Revenue Growth (YoY) | 3.70% |
| Shares Outstanding | $707.77M |
| Float | $630.64M |
| % Insiders | 10.73% |
| % Institutions | 84.49% |
Volatility is currently expanding
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
Danaher's Biotechnology segment posts 7% core revenue growth as bioprocessing demand strengthened, even as weaker product demand created headwinds.
Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (NYSE: DHR), today announced a $1 million commitment to support urgent, on-the-ground response to the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) and Uganda through Save the Children, the International Rescue Committee (IRC) and the World Food Program USA in support of the World Food Programme (WFP). The funding will be distributed across the three organizations to enable rapid, flexible response to evolving conditions on the ground.
Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in Merck (MRK).
Danaher (DHR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DHR crossed above the 20-day moving average, suggesting a short-term bullish trend.
Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?
WASHINGTON, June 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2026 on Tuesday, July 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
